What's changed: evidence updates and corrections log

Science and regulatory guidance evolve continuously. When health authorities release new prescribing guidance, clinical societies update treatment recommendations, or our editorial team corrects an error, we log every change here.

2026 Updates

February 12, 2026: FDA Approves Labeling Changes on Six MHT Formulations

• Action: FDA approved revised prescribing labels for six menopausal hormone therapy products, removing cardiovascular and dementia statements from the prominent boxed warning.
• Affected articles: Updated The FDA HRT boxed warning change, explained, Menopause treatment options, and Hot flashes in perimenopause.
• Clinical impact: Strengthens guidance that initiating therapy within 10 years of menopause or before age 60 provides favorable benefit-risk balance for moderate to severe vasomotor symptoms.

2025 Updates

November 10, 2025: FDA Safety Request to Hormone Manufacturers

• Action: FDA formally requested manufacturers update prescribing labels and eliminate the “lowest dose for shortest duration” restriction.
• Affected articles: Added to the regulatory timeline in our hormone therapy guides.

May 2025: Non-hormonal NK3 Receptor Guidelines

• Action: The Menopause Society issued updated clinical consensus recognizing neurokinin 3 receptor antagonists as effective first-line non-hormonal prescription options for vasomotor symptoms.
• Affected articles: Integrated into Hot flashes and Night sweats.

Submitting a correction

If you spot a factual error, broken link, or outdated citation in any article, please contact our editorial team. Material corrections are updated within 48 hours and documented in the relevant article's change log, alongside updates to our interactive evidence checker tool.